Semaglutide linked to better quality of life in diabetes and kidney disease, trial shows

Article excerpt

Semaglutide, a once-weekly injection already prescribed for diabetes and weight loss, delivered an unexpected bonus in a large clinical trial: patients with type 2 diabetes and chronic kidney disease reported substantially better quality of life. The improvement was significant enough that researchers quantified it as roughly eight additional days of full health annually. The FLOW trial, presented at the European Renal Association Congress, measured not just clinical outcomes but how patients actually felt day-to-day, a metric often overlooked in drug studies that focus narrowly on blood sugar or kidney function.